Biologic Mediations for Nasal Polyps
Biologic medications are a revolutionary treatment option for patients suffering from nasal polyps associated with chronic rhinosinusitis. Unlike traditional therapies such as corticosteroids or surgery, biologics work by targeting the underlying inflammation that causes polyp growth, offering long-term symptom relief.
What are Biologic Mediations for Nasal Polyps?
Dupixent (dupilumab) and Nucala (mepolizumab) are biologic medications used to treat nasal polyps, particularly in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). They are monoclonal antibodies that inhibit key proteins that play a role in the inflammatory process that creates polyps. Dupixent and Nucala are given as an injection under the skin, once every two to four weeks.
What are the benefits?
- Improved Breathing & Sense of Smell – Helps restore normal nasal function.
- Reduced Dependence on Steroids – Lowers the risks associated with long-term steroid use.
- Non-Surgical Alternative – Reduces or eliminates the need for surgery.
- Long-Term Relief – Provides sustained symptom control.
Who is a candidate?
Both medications are effective for managing chronic rhinosinusitis with nasal polyps, especially in cases that are difficult to control with steroids or other treatments. They are typically used when conservative treatments have failed, when patients have severe or recurrent nasal polyps, or when patients are not candidates for sinus surgery.
